The acquisition aligns with Grünenthal’s strategy to expand its product portfolio. Credit: fizkes / Shutterstock.

Grünenthal has announced the acquisition of US-based Valinor Pharma, along with its opioid-induced constipation (OIC) therapy Movantik, in a $250m deal which includes complete royalty obligations.

The transaction will be financed using Grünenthal’s available liquidity.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Movantik, known as Moventig outside the US, is an oral treatment for OIC in adults with chronic non-cancer pain.

The acquisition broadens Grünenthal’s portfolio of established treatments and strengthens its growing presence in the US market.

In 2023 Movantik generated gross sales exceeding $200m in the US.

See Also:

Grünenthal previously acquired the therapy in Europe as part of a joint venture (JV) with Kyowa-Kirin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the purchase of Valinor, Grünenthal now owns the worldwide rights to the product, excluding Canada.

Grünenthal US president Marv Kelly stated: “We are excited to welcome Valinor and expand our portfolio offering to pain specialists with Movantik.”

Since 2017, the company has added several products to its lineup, including Nebido, the European rights to Crestor and Nexium, and the worldwide rights to Vimovo, Qutenza and Zomig, with Japan as an exception for the latter two.

In 2023, Grünenthal also established a JV, Grünenthal Meds, with Kyowa Kirin International.

This JV manages a pain-management-focused portfolio of 13 brands.

Grünenthal has invested more than €2bn in successful mergers and acquisitions.

Its CEO Gabriel Baertschi stated: “As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio. “The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal.”